TY - JOUR
T1 - Tayside Screening For Cardiac Events (TASCFORCE) study
T2 - a prospective cardiovascular risk screening study
AU - Lambert, Matthew A.
AU - Houston, J. Graeme
AU - Littleford, Roberta
AU - Fitton, Catherine A.
AU - Struthers, Allan
AU - Sullivan, Frank
AU - Gandy, Stephen
AU - Belch, Jill J. F.
N1 - Funding Information:
The study consortium would like to thank the participants for taking part and CHSS/the Souter Foundation for the funding.
Funding Information:
This study was funded by Chest Heart and Stroke (Scotland) and the Souter Foundation.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022.
PY - 2022/10/21
Y1 - 2022/10/21
N2 - Purpose: Risk factor-based models struggle to accurately predict the development of cardiovascular disease (CVD) at the level of the individual. Ways of identifying people with low predicted risk who will develop CVD would allow stratified advice and support informed treatment decisions about the initiation or adjustment of preventive medication, and this is the aim of this prospective cohort study.Participants: The Tayside Screening for Cardiac Events (TASCFORCE) study recruited men and women aged≥40 years, free from known CVD, with a predicted 10-year risk of coronary heart disease<20%. If B-type natriuretic peptide (BNP) was greater than their gender median, participants were offered a whole-body contrast-enhanced MRI (WBCE-MRI) scan (cardiac imaging, whole-body angiography to determine left ventricular parameters, delayed gadolinium enhancement, atheroma burden). Blood, including DNA, was stored for future biomarker assays. Participants are being followed up using electronic record-linkage cardiovascular outcomes.Findings to date: 4423 (1740, 39.3% men) were recruited. Mean age was 52.3 years with a median BNP of 7.50 ng/L and 15.30 ng/L for men and women, respectively. 602 had a predicted 10-year risk of 10%-19.9%, with the remainder<10%. Age, female sex, ex-smoking status, lower heart rate, higher high-density lipoprotein and lower total cholesterol were independently associated with higher log10 BNP levels. Mean left ventricular mass was 129.2 g and 87.0 g in men and women, respectively.Future plans: The TASCFORCE study is investigating the ability of a screening programme, using BNP and WBCE-MRI, at the time of enrolment, to evaluate prediction of CVD in a population at low/intermediate risk. Blood stored for future biomarker analyses will allow testing/development of novel biomarkers. We believe this could be a new UK Framingham study allowing study for many years to come.Clinical trial registration: ISRCTN38976321.
AB - Purpose: Risk factor-based models struggle to accurately predict the development of cardiovascular disease (CVD) at the level of the individual. Ways of identifying people with low predicted risk who will develop CVD would allow stratified advice and support informed treatment decisions about the initiation or adjustment of preventive medication, and this is the aim of this prospective cohort study.Participants: The Tayside Screening for Cardiac Events (TASCFORCE) study recruited men and women aged≥40 years, free from known CVD, with a predicted 10-year risk of coronary heart disease<20%. If B-type natriuretic peptide (BNP) was greater than their gender median, participants were offered a whole-body contrast-enhanced MRI (WBCE-MRI) scan (cardiac imaging, whole-body angiography to determine left ventricular parameters, delayed gadolinium enhancement, atheroma burden). Blood, including DNA, was stored for future biomarker assays. Participants are being followed up using electronic record-linkage cardiovascular outcomes.Findings to date: 4423 (1740, 39.3% men) were recruited. Mean age was 52.3 years with a median BNP of 7.50 ng/L and 15.30 ng/L for men and women, respectively. 602 had a predicted 10-year risk of 10%-19.9%, with the remainder<10%. Age, female sex, ex-smoking status, lower heart rate, higher high-density lipoprotein and lower total cholesterol were independently associated with higher log10 BNP levels. Mean left ventricular mass was 129.2 g and 87.0 g in men and women, respectively.Future plans: The TASCFORCE study is investigating the ability of a screening programme, using BNP and WBCE-MRI, at the time of enrolment, to evaluate prediction of CVD in a population at low/intermediate risk. Blood stored for future biomarker analyses will allow testing/development of novel biomarkers. We believe this could be a new UK Framingham study allowing study for many years to come.Clinical trial registration: ISRCTN38976321.
KW - Male
KW - Humans
KW - Female
KW - Middle Aged
KW - Prospective Studies
KW - Cardiovascular Diseases/diagnosis
KW - Natriuretic Peptide, Brain
KW - Gadolinium
KW - Contrast Media
KW - Risk Factors
KW - Heart Disease Risk Factors
KW - Biomarkers
KW - Cholesterol
KW - Lipoproteins, HDL
KW - cardiology
KW - Magnetic Resonance Imaging
KW - cardiovascular imaging
UR - http://www.scopus.com/inward/record.url?scp=85140352052&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2022-063594
DO - 10.1136/bmjopen-2022-063594
M3 - Article
C2 - 36270757
SN - 2044-6055
VL - 12
JO - BMJ Open
JF - BMJ Open
IS - 10
M1 - e063594
ER -
